肺动脉高血压中的骨形态蛋白受体2型突变:右心室的视图
Cathelijne E van der Bruggen1, Chris M Happé1, Peter Dorfmüller1
1From Department of Pulmonology, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands (C.E.E.V.D.B., C.M.H., P.T., O.A.S., N.R., A.V.N., H.J.B., F.S.d.M.); Department of Physiology, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands (C.M.H., N.R., F.P.H., J.V.D.V., F.S.d.M.); Univ. Paris-Sud, Le Kremlin-Bicêtre, France (P.D., B.G., .M.H.); AP-HP, Service de Pneumologie, Centre de Référence de l'Hypertension Pulmonaire Sévère, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France (P.D., B.G., M.H.); INSERM999, LabEx LERMIT, Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France (P.D., B.G., M.H.); Department of Clinical Genetics, VU University Medical Center, Amsterdam, The Netherlands (A.C.H.); Department of Physics and Medical Technology, VU University Medical Center, Amsterdam, The Netherlands (J.T.M.); Department of Thoracic and Vascular Surgery and Heart-Lung Transplantation, Hôpital Marie-Lannelongue, Le Plessis Robinson, Paris-Sud University, France (O.M.); Department of Cardiology, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands (M.L.H.); and Department of Molecular Cell Biology, Laboratory of Experimental Cardiology, Leiden University Medical Center, Leiden, The Netherlands (M.-J.G.).
尽管肺动脉压力相似,但携带BMPR2基因突变的肺动脉高血压患者表现出较差的右心室功能. 这项研究研究了BMPR2突变对肺动脉高血压的右心室功能的影响.
科学领域:
- 心脏病学
- 遗传学
- 肺病学
背景情况:
- 肺动脉高血压 (PAH) 是一种严重影响心脏和肺部的疾病.
- 在PAH中,骨形态蛋白受体2 (BMPR2) 基因突变在右心室 (RV) 功能障碍中的作用尚未完全理解.
- 这项研究研究了BMPR2突变对PAH患者的RV功能的影响.
研究的目的:
- 确定BMPR2基因突变对肺动脉高血压中右心室压力过载的影响.
- 在有或没有BMPR2突变的PAH患者中比较RV功能.
- 探索心脏组织中潜在的分子和组织差异.
主要方法:
- 对95名PAH患者进行BMPR2突变的基因查.
- 使用右心导管和心脏核磁共振 (MRI) 在体内评估RV功能.
- 人类RV和左心室组织的分子和组织分析.
主要成果:
- 尽管肺动脉压力和肺血管阻力相似,但BMPR2突变携带者 (n=28) 的RV功能 (RV射出分数,心脏指数) 比非携带者明显差.
- 这些功能差异在治疗后仍然存在.
- 携带者和非携带者之间没有观察到TGF-β/ BMPR2信号,缩,缩,毛细血管密度,炎症或心脏代谢的显著差异.
结论:
- 与非携带者相比,患有BMPR2突变的PAH患者的右心室功能更严重受损,即使后负荷也相似.
- 观察到的RV功能的差异并不能通过TGF-β/ BMPR2信号传递或心脏适应机制的变化来解释.
- 需要进行进一步的研究,以阐明PAH的BMPR2突变载体中RV功能障碍的确切机制.
更多相关视频
10:20Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
Published on: January 16, 2013
03:45Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
